Apalutamide(ARN509)
- ARN 509; ARN-509
货号: abs810842
货号-规格 | 货期 | 价格 | 数量 |
abs810842-5mg | 1-2周 | ¥1046.00 | - + |
abs810842-10mg | 1-2周 | ¥1738.00 | - + |
abs810842-50mg | 1-2周 | ¥5965.00 | - + |

产品描述 | ||
描述 | ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment. | |
纯度 | >98% | |
储存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. | |
基本信息 | ||
别名 | ARN 509; ARN-509 | |
外观 | Powder | |
可溶性/溶解性 | DMSO 18 mg/mL (37.7 mM) Ethanol 5 mg/mL (10.47 mM) | |
生物活性 | ||
靶点 | Androgen Receptor | |
In vitro(体外研究) | ARN-509 ( | |
In vivo(体内研究) | ARN-509 (10 mg/kg/d, oral) inhibits tumor growth with decreased proliferative index and increased apoptotic rate in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dose dependently inhibits tumor growth with highest efficacy at dose of 30 mg/kg/day in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dosed at 10 mg/kg/d for 28 days results in a 3-fold reduction in prostates weight associated with lacking glandular secretory activity and 1.7-fold reduction in epididymis weight in adult male dogs. ARN-509 (10 mg/kg/d, oral) inhibits cell proliferation of prostate tissues in adult male dogs. ARN-509 is safe and well tolerated in 24 patients with metastatic CRPC who has progressed on prior treatments and peak plasma concentrations occurred 2 to 3 hours after administration. ARN-509 results in durable PSA declines at doses ranging from 30 to 300 mg in patients with metastatic CRPC. ARN-509 shows powerful anti-cancer activity and induces durable remissions long after therapy completion in castrate resistant prostate cancer mouse models. | |
温馨提示:本产品仅作科研实验使用,不支持临床等研究 |
- 实验方法 实验条件
共 0张,还能上传 8张 提交
- 提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
提交不成功?请联系info@absin.cn。
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。